U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07172802) titled 'A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors' on Aug. 28.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors
Study Start Date: April 22
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Metastatic Solid Tumor
Non-small Cell Lung Cancer (NSCLC)
Head and Neck (HNSCC)
Pancreatic Cancer
Renal Cell Carcinoma (RCC)
Intervention:
DRUG: GI-108
Dose level will be escalated fro...